UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1366-4
Program Prior Authorization/Notification
Medication Rezurock® (belumosudil)
P&T Approval Date 9/2021, 9/2022, 9/2023, 9/2024
Effective Date 11/17/2024
1. Background:
Rezurock is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years
and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two
prior lines of systemic therapy.1
Members will be required to meet the coverage criteria below.
2. Coverage Criteriaa:
A. Initial Authorization
1. Rezurock will be approved based upon both of the following criteria:
a. Diagnosis of chronic graft-versus-host disease (chronic GVHD)
-AND-
b. History of failure of at least two prior lines of systemic therapy [e.g., corticosteroids,
mycophenolate, tacrolimus, etc.]
Authorization will be issued for 12 months.
B. Reauthorization
1. Rezurock will be approved based on the following criterion:
a. Documentation of positive clinical response to Rezurock therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Rezurock [Package Insert]. Warrendale, PA: Kadmon Pharmaceuticals, LLC; April 2024.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
www.nccn.org . Accessed August 1, 2024.
Program Prior Authorization/Notification - Rezurock® ( belumosudil)
Change Control
9/2021 New program
9/2022 Annual review with no change to coverage criteria. Added state
mandate footnote.
9/2023 Annual review with no change to clinical criteria. Updated references.
9/2024 Annual review. Removed age criteria. Updated references.
© 2024 UnitedHealthcare Services, Inc.
2